Biotech · Private company
Ellipses Pharma
Track this companyFree. Adds Ellipses Pharma to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- AbemaciclibPhase 2 · Hormone Receptor-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ElacestrantPhase 2 · Hormone Receptor-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- EP0031Phase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- EP0057Phase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- EP0062Phase 2 · Hormone Receptor-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- EverolimusPhase 2 · Hormone Receptor-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ExemestanePhase 2 · Hormone Receptor-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 2 · Hormone Receptor-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Olaparib tabletsPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- Platinum chemotherapyPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerPHASE1_PHASE2 · RECRUITING · started Jan 11, 2023ClinicalTrials.gov NCT05573126 · fetched Nov 12, 2026
- A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered MalignanciesPHASE1_PHASE2 · RECRUITING · started Sep 30, 2022ClinicalTrials.gov NCT05443126 · fetched Nov 12, 2026
- EP0057 in Combination With Olaparib in Advanced Ovarian CancerPHASE2 · COMPLETED · started Dec 14, 2020ClinicalTrials.gov NCT04669002 · fetched Nov 12, 2026